Erytech Pharma SA Financials

ERYPDelisted Stock  USD 0.78  0.04  4.88%   
Based on the key measurements obtained from Erytech Pharma's financial statements, Erytech Pharma SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.
  
Understanding current and past Erytech Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Erytech Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Erytech Pharma's assets may result in an increase in income on the income statement.

Erytech Pharma Stock Summary

Erytech Pharma competes with Genfit, Eliem Therapeutics, HCW Biologics, Aptorum Group, and Surrozen. ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. The company was incorporated in 2004 and is headquartered in Lyon, France. Erytech Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS29604W1080
Business Address60 Avenue Rockefeller,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.erytech.com
Phone33 4 78 74 44 38
CurrencyUSD - US Dollar

Erytech Pharma Key Financial Ratios

Erytech Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Erytech Pharma's current stock value. Our valuation model uses many indicators to compare Erytech Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Erytech Pharma competition to find correlations between indicators driving Erytech Pharma's intrinsic value. More Info.
Erytech Pharma SA is rated # 2 in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Erytech Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Erytech Pharma Market Pulse

 Quote0.78
 Change(%)  4.88 
 Change0.04 
 Open0.82
 Low0.78
 High0.84
 Volume0
 ExchangeNASDAQ

Steps to analyze company Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Erytech Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Erytech has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Erytech Pharma's financials are consistent with your investment objective using the following steps:
  • Review Erytech Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Erytech Pharma's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Erytech Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Erytech Pharma's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Erytech Pharma Thematic Clasifications

Erytech Pharma SA is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas

Erytech Pharma November 30, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Erytech Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Erytech Pharma SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Erytech Pharma SA based on widely used predictive technical indicators. In general, we focus on analyzing Erytech Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Erytech Pharma's daily price indicators and compare them against related drivers.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Consideration for investing in Erytech Stock

If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Bonds Directory
Find actively traded corporate debentures issued by US companies
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume